Niagen Bioscience, Inc. (NASDAQ:NAGE) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Niagen Bioscience, Inc. (NASDAQ:NAGE) have received an average recommendation of “Moderate Buy” from the five ratings firms that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $14.2750.

Several equities analysts recently commented on NAGE shares. Weiss Ratings reiterated a “hold (c)” rating on shares of Niagen Bioscience in a report on Thursday, January 22nd. Canaccord Genuity Group dropped their target price on Niagen Bioscience from $16.00 to $14.00 and set a “buy” rating for the company in a research report on Wednesday, November 5th.

Niagen Bioscience Stock Performance

NASDAQ:NAGE opened at $5.68 on Friday. The firm has a market capitalization of $453.32 million, a PE ratio of 23.67 and a beta of 2.35. The stock’s fifty day moving average is $6.42 and its 200 day moving average is $7.84. Niagen Bioscience has a fifty-two week low of $5.25 and a fifty-two week high of $14.69.

Niagen Bioscience (NASDAQ:NAGE) last posted its quarterly earnings data on Tuesday, November 4th. The company reported $0.05 EPS for the quarter, topping the consensus estimate of $0.02 by $0.03. Niagen Bioscience had a net margin of 16.38% and a return on equity of 24.13%. The company had revenue of $33.99 million during the quarter, compared to analyst estimates of $31.30 million.

Insider Transactions at Niagen Bioscience

In other Niagen Bioscience news, CFO Ozan Pamir acquired 4,465 shares of the company’s stock in a transaction that occurred on Friday, November 14th. The stock was bought at an average price of $6.81 per share, for a total transaction of $30,406.65. Following the acquisition, the chief financial officer directly owned 7,372 shares in the company, valued at $50,203.32. The trade was a 153.59% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 9.39% of the stock is currently owned by insiders.

Institutional Trading of Niagen Bioscience

A number of large investors have recently made changes to their positions in NAGE. Financial Consulate Inc. purchased a new position in Niagen Bioscience in the 3rd quarter worth about $33,000. New York State Teachers Retirement System purchased a new stake in Niagen Bioscience in the 4th quarter valued at about $30,000. Ameritas Investment Partners Inc. bought a new position in Niagen Bioscience in the 3rd quarter worth about $45,000. State of Alaska Department of Revenue bought a new position in Niagen Bioscience in the 3rd quarter worth about $44,000. Finally, North Star Investment Management Corp. purchased a new position in shares of Niagen Bioscience during the third quarter worth approximately $47,000. 15.41% of the stock is owned by hedge funds and other institutional investors.

About Niagen Bioscience

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services.